<<
>>

Introduction

Human leishmaniasis is a sandfly-mediated parasitic disease that can lead to severe conditions in individuals especially with underdeveloped immune system. It usually affects people living in developing tropical countries and has high mor­tality rates [1].

Transmission of the parasite starts with an infected sandfly bite. After getting bit by a female sandfly vector carrying the promastigote form of the Leishmania protozoan, the promastigotes transform into amastigote form in mam­malian hosts [2]. Once amastigotes enter the cells, immune system starts reacting to it. Phagocytes absorb the parasite, and destructive mechanism is initiated in order to kill the parasite. However, parasite has different ways of preventing or lowering the activity of immune system, and three distinct forms of leishmaniasis can be observed as a result which are cutaneous leishmaniasis (CL), visceral leishmani­asis (VL), and mucocutaneous leishmaniasis (ML). CL usually occurs around the uncovered sites such as face, neck, and extremities which are susceptible to sandfly bite and often can result in the formation of ulcers or nodules around exposed areas. In certain conditions, macrophages infected by the parasites at the initial bite site spread among the reticuloendothelial system causing VL. Abnormal growth of internal organs such as the spleen and liver is common in VL, and it can cause death if necessary treatment methods are not applied. Another form of leishmaniasis is the ML in which parasites enter the mucocutaneous tissue, and its effects are usually seen around the oral and upper respiratory tract [3].

Leishmaniasis is considered to be an endemic disease effecting more than 98 countries with a global prevalence of 12 million people. Among different types of disease, CL makes up great percentage of the total amount of cases compared to other two. East Africa, Brazil, and Indian subcontinent are hot spots for VL cases, whereas CL cases are high in the Middle East, Mediterranean region, Central Asia, and Latin American countries [4].

In European countries where leishmaniasis is not endemic, people traveling to endemic regions for various reasons such as military duty, tourism work, and vacation are the major cause of leishmaniasis occurrence [5].

There are more than 20 Leishmania species responsible from leishmaniasis [3]. In general, Leishmania major causes CL, Leishmania donovani causes VL, and Leishmania infantum results in both CL and VL [3]. These species can be further classified into subgenera depending on anatomical varieties of infection sites. Old World sandfly species are common in desert and semidry areas, whereas New World sandfly species transmit the disease to human near forest habitation [6]. Leishmania parasite has promastigote form in sandfly and amastigote form in mam­malians. It can be transmitted by the vectors from an animal carrying this parasite or humans affected by VL. Amastigotes develop within the phagocytes and spread to other macrophages as a result of cell lysis. Once a sandfly bites an infected host, amastigotes then transform into promastigote form inside the sandfly restarting the transmission process for the next host that will be infected.

Leishmaniasis is ranked second in mortality right after malaria and ranked fourth in terms of morbidity among other communicable diseases [2]. HIV out­break in the 1990s resulting in HIV/VL coinfection and general global warming of the world increasing the possible habitat for the sandfly led to doubling the amount of cases from 1987 to 2014 despite developing medical technologies [6]. It is esti­mated that each year around 400,000 people are having VL with a mortality rate of 10% going up to 20% in some areas [2, 3]. The Mediterranean region, Western Asia, and the Americas make up the 90% of 1 million CL cases, whereas ML is represented by 35,000 cases in these regions [3]. Among the other common forms of the disease, CL has the highest amount of cases reported each year. On the other hand, VL is the most fatal one where death usually occurs 2 years after the first transmission.

There are 98 countries and territories with Leishmania cases recorded each year [7]. It affects around 12 million people worldwide, and 1.5-2 million new cases are reported each year. Being an ignored tropical disease, leishmaniasis has the high­est prevalence in poor countries such as India, Brazil, Ethiopia, and Afghanistan. Notably, there has been an increase in the CL case reports for Syria in the Middle East, Algeria in the Mediterranean, and India [6]. Poor housing, insufficient sanitary conditions, poor waste management, poverty, malnutrition, and change in climate conditions such as temperature, rainfall, and humidity are common features of these countries. Children living in these countries are considered the main reason of parasite transmission as they are the most vulnerable population group to sandfly bite.

Among species, L. major shows the biggest geographical distribution in the Middle East region compared to Leishmania tropica and Leishmania infantum [8]. L. infantum caused zoonotic and L. tropica caused anthroponotic transmissions to occur. Domestic dogs, rodents, and wild animals in endemic regions hold epidemiological importance as they take part in transmission of the parasite by serving as reservoirs.

Parasites can only reach infective stages in certain species of sandfly which as a result limits its transmission [9]. In addition, parasite-vector contact is rare for great majority of the sandfly species [10]. Epidemiological concerns about the leishmani­asis have increased greatly in the last 30 years. HIV/Leishmania coinfection, sand­flies becoming more apparent in areas that they were less present such as the United States and Canada, and great risk of Leishmania gaining resistance to drugs over time make it a high-risk factor globally [11]. Another major concern for leishmani­asis is the increased resistance gain by parasite to current treatment methods which makes it even more dangerous considering there is an ongoing effort to develop a human vaccine against the disease [12].

Here, we aim to provide a general conceptualization of leishmaniasis by summa­rizing the historical development of the disease to provide a better understanding for possible future approaches.

2.

<< | >>
Source: Savic Sara (ed.). Vectors and Vector-Borne Zoonotic Diseases. ITexLi,2019. — 110 p. 2019

More on the topic Introduction: